Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Kim, Kyung | - |
dc.contributor.author | Kwon, Ghee-Young | - |
dc.contributor.author | Lee, Su Jin | - |
dc.contributor.author | Park, Se Hoon | - |
dc.date.available | 2020-02-27T10:40:53Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-07-31 | - |
dc.identifier.issn | 1471-2490 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3556 | - |
dc.description.abstract | Background: Recent studies suggest that FGFR3 is a potential therapeutic target in urothelial carcinoma (UC). The purpose of this study was to evaluate the rates and types of FGFR3 aberrations in patients with muscle-invasive UC who received radical resection. Methods: We analyzed surgical tumor samples from 74 UC patients who had received radical cystectomy (n = 40) or ureteronephrectomy (n = 34). Ion AmpliSeq Cancer Hotspot Panel v2 and nCounter Copy Number Variation Assay were used to detect FGFR3 aberrations. Results: Fifty-four patients (73%) had high-grade tumors, and 62% had lymph node involvement. Sixteen patients (22%) harbored FGFR3 alterations, the most common of which was FGFR3 mutations (n = 13): Y373C (n = 3), N532D (n = 3), R248C (n = 2), S249C (n = 1), G370C (n = 1), S657S (n = 1), A797P (n = 1), and 746_747InsG (n = 1). Three additional patients had a FGFR3-TACC3 rearrangement. The frequency of FGFR3 aberrations was higher in bladder UC (25%) than in UC of the renal pelvis and ureter (18%) but the difference was not statistically significant (P = 0.444). Genes that were co-aberrant with FGFR3 included APC (88%), PDGFRA (81%), RET (69%), and TP53 (69%). Conclusions: We report the frequency and types of FGFR3 aberrations in Korean patients with UC. Patients with FGFR3 mutations or FGFR3-TACC3 fusion may constitute potential candidates for a novel FGFR-targeted therapy in the perioperative setting. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | BMC UROLOGY | - |
dc.subject | GENE FUSIONS | - |
dc.subject | MOLECULAR CHARACTERIZATION | - |
dc.subject | CELL-CARCINOMA | - |
dc.subject | PHASE-I | - |
dc.subject | BLADDER | - |
dc.subject | MUTATIONS | - |
dc.subject | GUIDELINES | - |
dc.subject | INHIBITOR | - |
dc.subject | SURVIVAL | - |
dc.title | Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000440436100002 | - |
dc.identifier.doi | 10.1186/s12894-018-0380-1 | - |
dc.identifier.bibliographicCitation | BMC UROLOGY, v.18 | - |
dc.identifier.scopusid | 2-s2.0-85051220333 | - |
dc.citation.title | BMC UROLOGY | - |
dc.citation.volume | 18 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Urothelial carcinoma | - |
dc.subject.keywordAuthor | FGFR | - |
dc.subject.keywordAuthor | Mutation | - |
dc.subject.keywordAuthor | Fusion | - |
dc.subject.keywordPlus | GENE FUSIONS | - |
dc.subject.keywordPlus | MOLECULAR CHARACTERIZATION | - |
dc.subject.keywordPlus | CELL-CARCINOMA | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | BLADDER | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.